NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Alphabet-C
GOOG
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.680
- +0.060+3.70%
Close Dec 20 16:00 ET
- 1.640
- -0.040-2.38%
Post 20:01 ET
31.68MMarket Cap-1.79P/E (TTM)
1.680High1.607Low40.23KVolume1.620Open1.620Pre Close65.78KTurnover0.34%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High1.94P/B19.86MFloat Cap0.45052wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM4.49%Amplitude0.420Historical Low1.635Avg Price1Lot Size
Chemomab Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -15.91%-23.61M | -31.31%-7.49M | -93.64%-7.19M | -64.62%-20.37M | -97.06%-5.7M | -103.68%-5.26M | -1.68%-5.7M | -187.01%-3.71M | -136.05%-12.37M | -86.11%-2.89M |
| Net income from continuing operations | 12.39%-24.22M | -28.76%-7.97M | -71.49%-8.75M | -121.56%-27.65M | -64.26%-8.27M | -172.24%-8.08M | -123.47%-6.19M | -199.53%-5.1M | -109.68%-12.48M | -158.12%-5.04M |
| Depreciation and amortization | 15.52%67K | 14.29%16K | 23.08%16K | 70.59%58K | 27.27%14K | 88.89%17K | 100.00%14K | 85.71%13K | 41.67%34K | 83.33%11K |
| Change In working capital | -123.66%-948K | 40.21%-171K | 110.87%1.07M | 305.59%4.01M | 61.62%1.82M | 3,280.65%1.97M | 91.52%-286K | 40.17%506K | -451.17%-1.95M | 214.57%1.12M |
| -Change in receivables | 1,510.94%903K | 99.73%-3K | 324.24%814K | 96.89%-64K | 516.09%536K | 129.95%883K | 56.69%-1.12M | -736.84%-363K | -1,978.79%-2.06M | 229.85%87K |
| -Change in payables and accrued expense | -135.50%-1.13M | -229.51%-531K | -62.68%315K | 3,152.88%3.18M | 48.56%1.24M | 362.16%679K | 145.56%410K | 285.39%844K | -122.61%-104K | 155.66%836K |
| -Change in other current liabilities | ---- | ---- | -125.00%-3K | ---- | ---- | --0 | ---27K | --12K | ---- | ---- |
| -Change in other working capital | -180.80%-724K | -20.18%360K | -553.85%-59K | 320.66%896K | -89.00%22K | 319.25%410K | 292.17%451K | -84.71%13K | 9.79%213K | 106.19%200K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -15.91%-23.61M | -31.31%-7.49M | -93.64%-7.19M | -64.62%-20.37M | -97.06%-5.7M | -103.68%-5.26M | -1.68%-5.7M | -187.01%-3.71M | -136.05%-12.37M | -86.11%-2.89M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -18.71%15.88M | -347.13%-4.27M | 505.88%14.43M | 143.23%19.53M | 147.75%9.35M | 221.48%6.07M | 108.38%1.73M | 119,200.00%2.38M | -72,780.65%-45.19M | -652,600.00%-19.58M |
| Net PPE purchase and sale | 95.59%-3K | 81.82%-2K | 92.86%-1K | 71.06%-68K | 99.23%-1K | ---42K | 89.22%-11K | -366.67%-14K | -518.42%-235K | -12,900.00%-130K |
| Net investment purchase and sale | ---- | -345.45%-4.27M | 502.38%14.43M | ---- | ---- | ---- | --1.74M | --2.4M | ---- | ---- |
| Net other investing changes | -18.97%15.88M | ---- | ---- | 143.61%19.6M | 148.07%9.35M | ---- | ---- | ---- | ---44.95M | ---19.45M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -18.71%15.88M | -347.13%-4.27M | 505.88%14.43M | 143.23%19.53M | 147.75%9.35M | 221.48%6.07M | 108.38%1.73M | 119,200.00%2.38M | -72,780.65%-45.19M | -652,600.00%-19.58M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 533.66%3.5M | -101.32%-808K | -972.84%-869K | 154.17%39K | 1,185.77%61.07M | -114.39%-81K | ||||
| Net common stock issuance | 468.45%3.5M | ---- | ---- | -101.62%-951K | -945.05%-951K | --0 | ---- | ---- | 1,575.34%58.64M | -118.20%-91K |
| Proceeds from stock option exercised by employees | --0 | ---- | ---- | 1,330.00%143K | 720.00%82K | --39K | ---- | ---- | -99.20%10K | -98.22%10K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --2.43M | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 533.66%3.5M | 6,118.18%1.37M | --0 | -101.32%-808K | -972.84%-869K | 154.17%39K | -99.84%22K | --0 | 1,185.77%61.07M | -114.39%-81K |
| Net cash flow | ||||||||||
| Beginning cash position | -10.79%13.6M | 49.81%20.84M | -10.79%13.6M | 29.97%15.24M | -71.38%10.82M | -78.09%9.96M | -76.11%13.91M | 29.97%15.24M | -4.51%11.73M | 197.01%37.8M |
| Current changes in cash | -157.02%-4.23M | -162.80%-10.39M | 645.22%7.25M | -146.81%-1.65M | 112.32%2.78M | 111.21%858K | 69.08%-3.95M | -102.86%-1.33M | 734.30%3.51M | -2,166.93%-22.56M |
| End cash Position | -31.10%9.37M | 4.98%10.46M | 49.81%20.84M | -10.79%13.6M | -10.79%13.6M | -71.38%10.82M | -78.09%9.96M | -76.11%13.91M | 29.97%15.24M | 29.97%15.24M |
| Free cash flow | -15.54%-23.61M | -31.09%-7.49M | -92.94%-7.19M | -62.04%-20.44M | -88.38%-5.7M | -105.31%-5.3M | -0.05%-5.71M | -187.42%-3.73M | -138.88%-12.61M | -94.60%-3.03M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.